Cipro

# Cipro ## Overview - **Classification**: Fluoroquinolone antibiotic. - **Mechanism**: Inhibits bacterial DNA gyrase and topoisomerase IV, crucial enzymes for bacterial DNA replication. ## Primary Indications 1. **Complicated Urinary Tract Infections (cUTI)/Pyelonephritis**: Treatment of severe UTIs. 2. **Intra-abdominal Infections**: Often used in combination for gram-negative coverage. 3. **Infectious Diarrhea**: Caused by susceptible organisms (e.g., E. coli, Salmonella, Shigella). 4. **Bone and Joint Infections**: Due to susceptible gram-negative bacteria. 5. **Anthrax (Post-exposure prophylaxis)**: For inhalation anthrax. ## Adult Dosing ### Standard Dosing **Complicated UTI / Pyelonephritis** - **Dose**: **500 mg** PO or **400 mg** IV - **Frequency**: Every **12 hours** - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 7 to 14 days **Infectious Diarrhea** - **Dose**: **500 mg** - **Frequency**: Every **12 hours** - **Route**: PO - **Duration**: 5 to 7 days (or 3 days for traveler's diarrhea) ### Dose Adjustments - **Renal Impairment**: - CrCl 30-50 mL/min: No adjustment for standard doses. - CrCl <30 mL/min: Reduce dose by 50% (e.g., **250 mg PO** or **200 mg IV** every 12 hours). - Hemodialysis/Peritoneal Dialysis: Administer dose after dialysis. - **Hepatic Impairment**: Generally no dose adjustment needed; use with caution in severe cases. - **Elderly Patients**: Adjust dose based on renal function and monitor for adverse effects. ## Pediatric Dosing *(Use of fluoroquinolones in pediatrics is generally reserved for severe infections where other agents are ineffective or contraindicated, due to risk of musculoskeletal toxicity.)* ### Neonates (0-28 days) - **Not recommended**. Limited data, potential for musculoskeletal harm. - **Special Notes**: Consider only if no alternative exists for life-threatening infections (e.g., MDR Gram-negative sepsis). ### Infants (1-12 months) - **Dose**: **10-15 mg/kg** (oral or IV) - **Frequency**: Every **12 hours** - **Maximum**: **400 mg/dose** (IV), **500 mg/dose** (oral) - **Special Notes**: Reserved for specific severe infections (e.g., complicated UTI, pyelonephritis) when benefits outweigh risks. ### Children (1-12 years) - **Dose**: **10-20 mg/kg** (oral or IV) - **Frequency**: Every **12 hours** - **Maximum**: **750 mg/dose** (oral), **400 mg/dose** (IV) - **Special Notes**: Monitor closely for joint or tendon pain. Oral suspension is available. ### Adolescents (13-18 years) - **Dose**: Generally follows **adult dosing guidelines**. - **Maximum**: **Adult maximum dose** (e.g., **750 mg PO** or **400 mg IV** every 12 hours). ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to ciprofloxacin or other fluoroquinolones. - **Absolute**: Concomitant use with **tizanidine** (risk of severe hypotension). - **Relative**: History of **tendon disorders** related to fluoroquinolone use. ### Common Adverse Effects - **Common (1-10%)**: Nausea, diarrhea, abdominal pain, headache, dizziness, insomnia. - **Serious but Rare**: - **Tendonitis/Tendon Rupture**: Can occur hours to months after starting. - **Peripheral Neuropathy**: May be irreversible. - **CNS Effects**: Seizures, psychosis, increased intracranial pressure. - **QT Prolongation**: Risk of Torsades de Pointes. - **Aortic Aneurysm/Dissection**: Increased risk, especially in elderly. - **Clostridioides difficile-associated diarrhea (CDAD)**. - **Dysglycemia**: Both hypoglycemia and hyperglycemia reported. - **Photosensitivity**: Severe sunburn-like reactions. ### Key Drug Interactions - **Polyvalent Cations (Antacids, Iron, Zinc, Sucralfate)**: Significantly reduced cipro absorption. Administer cipro **2 hours before or 6 hours after** these agents. - **Theophylline**: Cipro inhibits its metabolism, increasing theophylline levels and toxicity. Monitor theophylline levels. - **Warfarin**: May enhance anticoagulant effect. Monitor INR frequently. - **Corticosteroids**: Increased risk of tendon rupture. Use with caution. - **Class IA/III Antiarrhythmics, TCAs**: Increased risk of QT prolongation. Avoid co-administration. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (CrCl). - **During Treatment**: - Monitor for signs/symptoms of tendon pain, swelling, or rupture. - Assess for new or worsening neurological symptoms (numbness, tingling). - Monitor blood glucose in diabetic patients. - Monitor INR if patient is on warfarin. - **Clinical Signs**: Advise patients to report any sudden pain in joints/tendons, numbness, tingling, or severe diarrhea. ## Clinical Pearls - 💡 **Black Box Warning**: Ciprofloxacin carries warnings for **tendonitis/rupture, peripheral neuropathy, CNS effects**, and **exacerbation of myasthenia gravis**. - 💡 **Administration**: Administer oral dose with a full glass of water. Do not take with dairy products or calcium-fortified juices alone. - 💡 **Hydration**: Ensure adequate hydration to prevent crystalluria. - 💡 **Photosensitivity**: Advise patients to avoid excessive sun exposure and use protective measures (clothing, sunscreen). > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.